Idylla NRAS-BRAF Mutation Assay

About Biocartis

Founded in 2007, Biocartis has established itself as a leader in automated, rapid molecular diagnostics with its proprietary Idylla™ platform. Its core mission is to make molecular testing actionable, easy, fast, and suitable for any lab, thereby enabling personalized medicine worldwide. Key achievements include securing FDA approval for its Idylla MSI Test and building a broad menu of RUO and IVD assays, primarily in oncology. The company's strategy revolves around expanding its test menu, deepening market penetration in the US and Europe, and leveraging partnerships to drive platform adoption.

Therapeutic Areas